A new post-grant review at the Patent Trial and Appeal Board could be one to watch for companies operating in the dental implant and broader medical-device space. On August 11, 2026, Straumann USA, LLC filed PGR2026-00070, asking the PTAB to review a recently issued patent. Although the public docket entry identifies the proceeding by petitioner name, the core significance lies in what a PGR allows: a broad-based validity attack in the first nine months after patent issuance, often raising issues that go well beyond prior art.

In this proceeding, Straumann USA, LLC is the petitioner challenging the patentability of claims in the patent at issue, while the unnamed patent owner will be defending the newly granted rights before the Board. Because this is a post-grant review rather than an inter partes review, the grounds for challenge are potentially expansive. A PGR can include arguments under 35 U.S.C. §§ 101, 102, 103, and 112, meaning petitioners may test not only novelty and obviousness, but also patent-eligibility, written description, enablement, and indefiniteness.

At this early stage, practitioners should expect the petition to frame the dispute around whether the challenged claims were granted too broadly, too vaguely, or without adequate support in the specification. For patent owners, that makes PGR proceedings especially high stakes: unlike IPRs, they can force a defense of claim drafting quality and disclosure sufficiency, not just the prior-art record. For petitioners, PGR remains one of the most powerful tools for attacking a fresh patent before district court litigation fully develops.

This filing is particularly relevant for IP counsel in regulated product markets. Dental and implant technologies often rely on layered patent portfolios covering devices, surface treatments, workflows, and surgical methods. A PTAB challenge by an established industry player like Straumann may offer clues about competitive positioning, freedom-to-operate concerns, and how major players are using administrative review to manage risk early.

Patent prosecutors should also pay attention to how the Board handles any disclosure-based attacks in this case. Decisions in PGRs can provide practical guidance on claim support, technical detail, and functional claiming in life-sciences and med-tech patents. Litigators, meanwhile, will be watching for institution trends and any estoppel implications if related disputes emerge elsewhere.

As the petition, preliminary response, and any institution decision are added to the docket, this case may become a useful study in early-stage patent enforcement pressure and PTAB strategy in the medical-device sector.

View full case on Docket Alarm